icon-folder.gif   Conference Reports for NATAP  
October 3 -7, 2019
San Francisco, CA
Back grey_arrow_rt.gif
Long-Term Efficacy, Safety and Durability of CAB
and RPV as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results

  IDWeek Oct 2-6 2019 Wash DC
Reported by Jules Levin
David A Margolis1, Kenneth C Sutton1, Jerome De Vente2, Roger LeBlanc3,
Edwin DeJesus4, Graham Smith5, Anthony Mills6, Jean-Guy Baril7, Marty St. Clair1, Britt S Stancil8, Peter E Williams9, William R Spreen1
1ViiV Healthcare, Research Triangle Park, North Carolina, USA; 2Long Beach Education and Research Consultants, Long Beach, California, USA; 3Clinique OPUS Inc., Quebec, Montreal, Canada; 4Orlando Immunology Center, Orlando, Florida, USA; 5Maple Leaf Research, Toronto, Ontario, Canada; 6Men's Health Foundation, Los Angeles, California, USA; 7Clinique Medicale Quartier Latin, Québec, Montreal, Canada; 8GlaxoSmithKline, Research Triangle Park, North Carolina, USA; 9Janssen Research and Development, Beerse, Belgium.